Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin-Based Chemotherapy in Non-Small Cell Lung Cancer
NCT00003240Phase 3
Key facts
- Status
- Unknown
- Start
- Oct 1995
- Countries
- 1
- Sponsor
- National Cancer Institute
- Modality
- Small Molecules
- Drugs
- cisplatin
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 3, randomised, open-label trial of cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Standard Therapy
Patients undergo primary surgery, radical radiotherapy, radiotherapy with surgery, or best supportive care.
Standard Therapy + Cisplatin-Based Chemotherapy
Patients undergo standard therapy plus one of four cisplatin-based chemotherapy regimens (Regimen A, B, C, or D).
03
Who it enrols
Adult patients with histologically confirmed non-small cell lung cancer treated with primary surgery, radical radiotherapy, surgery plus radiotherapy, or best supportive care, with no prior chemotherapy and adequate renal function.
04
Endpoints
Primary
Overall Survival
Beyond the preview
Go deeper on NCT00003240.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003240.